Absci (ABSI) Income from Continuing Operations (2020 - 2026)
Absci (ABSI) reported Income from Continuing Operations of 29599000.0 for Q1 2026, down 12.35% on a YoY basis from 33768468.97 in Q1 2025, and little changed sequentially from 29562000.0 in Q4 2025.
Absci (ABSI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Income from Continuing Operations data on file, last reported at 29599000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 12.35% year-over-year to 29599000.0; the trailing twelve-month figure through Mar 2026 stood at 118436000.0 (down 10.2% YoY), and the FY2025 full-year result was 115183000.0, down 11.71% from the prior year.
- Income from Continuing Operations held at 29599000.0 in Q1 2026, from 29562000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19471000.0 in Q4 2022 to a low of 41672000.0 in Q2 2023.
- A 5-year average of 27256352.94 and a median of 27398000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 169.62% in 2022 and surged 40.61% in 2024, its largest moves.
- Tracing ABSI's Income from Continuing Operations over 5 years: stood at 19471000.0 in 2022, then dropped by 20.92% to 23545000.0 in 2023, then declined by 23.1% to 28983000.0 in 2024, then declined by 2.0% to 29562000.0 in 2025, then dropped by 0.13% to 29599000.0 in 2026.
- Business Quant data shows ABSI's Income from Continuing Operations at 29599000.0 in Q1 2026, 29562000.0 in Q4 2025, and 28706000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Absci | 1.16 Bn | 1.03 Bn | - | -29.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.60 Mn |
| Dec 31, 2025 | -29.56 Mn |
| Sep 30, 2025 | -28.71 Mn |
| Jun 30, 2025 | -30.57 Mn |
| Mar 31, 2025 | -26.35 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -27.40 Mn |
| Jun 30, 2024 | -24.75 Mn |
| Mar 31, 2024 | -21.98 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -21.99 Mn |
| Jun 30, 2023 | -41.67 Mn |
| Mar 31, 2023 | -23.36 Mn |
| Dec 31, 2022 | -19.47 Mn |
| Sep 30, 2022 | -27.26 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -29.49 Mn |
| Dec 31, 2021 | -25.17 Mn |
| Sep 30, 2021 | -23.63 Mn |
| Jun 30, 2021 | -41.22 Mn |